Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa proof-of-concept study of TAC-201 in cedar pollinosis
jRCT2080221355Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cedar pollinosis and seasonal allergic rhinitis (SAR) comparing TAC-201 0.25 mg with Placebo (2 arms).
02
Drugs
TAC-201
03
Conditions
cedar pollinosisseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2080221355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221355.